Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
公司代碼PGEN
公司名稱Precigen Inc
上市日期Aug 08, 2013
CEOSabzevari (Helen)
員工數量143
證券類型Ordinary Share
年結日Aug 08
公司地址20374 Seneca Meadows Parkway
城市GERMANTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編20876
電話13015569900
網址https://precigen.com/
公司代碼PGEN
上市日期Aug 08, 2013
CEOSabzevari (Helen)